Search Results 1-10 of 14756 for TNF
Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor (TNF) agents have ...
They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the balancing acts of medicine, the anti-inflammatory action of ...
Rheumatoid arthritis is an autoimmune disorder characterized by chronic inflammation, including high levels of a cytokine called tumor necrosis factor, or TNF.
The purpose of this study is to compare the effectiveness of specific therapies to treat children with CD and UC/IBD-U refractory to anti-TNF therapy.
About this study. The purpose of this study is to evaluate infliximab drug levels and anti-infliximab antibody levels in HiSCR50/IHS4 responders versus ...
Ting's lab studies primarily post-translational mechanisms that dictate cell survival versus death in response to tumor necrosis factor (TNF). Even though TNF ...
* Documented history of previous use of \>= 1 tumor necrosis factor (TNF) inhibitor for HS for at least 12 weeks and/or 1 approved non-anti-TNF biologic ...
A Study Of The Efficacy And Safety Of Etrolizumab In Ulcerative Colitis Participants Who Are Refractory To Or Intolerant Of Tumor Necrosis Factor (TNF) ...
... tumor necrosis factor-alpha (TNF-a) antagonists. Unlike some previous research comparing JAK and TNF-a antagonists, the Mayo Clinic study focused ...
... Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ultimately require surgery despite ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.